patient_id stringlengths 12 12 | record_id stringlengths 11 11 | cancer_type stringclasses 1
value | histology stringclasses 3
values | stage_at_diagnosis stringclasses 3
values | driver_mutation stringclasses 7
values | pd_l1_tps_percent int64 5 41 | tmb_mutations_per_mb float64 1.5 25 | age_at_diagnosis int64 38 90 | sex stringclasses 2
values | ecog_performance_status int64 0 4 | smoking_pack_years int64 0 111 | primary_tumor_size_cm float64 2 10 | metastatic_sites_count int64 0 11 | first_line_regimen stringclasses 6
values | overall_survival_months float64 4 83 | censored bool 2
classes | msi_status stringclasses 2
values | record_generation_timestamp stringdate 2026-03-15 05:35:56 2026-03-15 05:36:02 | synthetic_source stringclasses 1
value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
ANODE_442657 | REC_0005201 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 23 | 6.2 | 64 | female | 0 | 7 | 6.4 | 2 | entrectinib 600 mg daily | 17.1 | true | MSS | 2026-03-15T05:35:58.133162+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_768749 | REC_0005202 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 22 | 4.1 | 66 | male | 0 | 20 | 4.2 | 4 | sotorasib 960 mg daily | 7.8 | false | MSS | 2026-03-15T05:35:58.133398+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_997491 | REC_0005203 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 23 | 10.1 | 64 | female | 1 | 12 | 5.5 | 4 | alectinib 600 mg BID | 8.8 | true | MSI-H | 2026-03-15T05:35:58.133635+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_379602 | REC_0005204 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 27 | 5.4 | 75 | female | 2 | 24 | 3.9 | 6 | carboplatin + paclitaxel + pembrolizumab | 10.1 | true | MSS | 2026-03-15T05:35:58.133865+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_458911 | REC_0005205 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 29 | 9.4 | 71 | female | 2 | 10 | 5.2 | 4 | entrectinib 600 mg daily | 15.3 | false | MSS | 2026-03-15T05:35:58.134097+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_240736 | REC_0005206 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 26 | 11.6 | 66 | female | 0 | 18 | 5.8 | 7 | sotorasib 960 mg daily | 10.9 | false | MSS | 2026-03-15T05:35:58.134328+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_184672 | REC_0005207 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 30 | 11.2 | 67 | female | 1 | 16 | 5.5 | 9 | pembrolizumab 200 mg q3w | 8.3 | true | MSI-H | 2026-03-15T05:35:58.134560+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_682465 | REC_0005208 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 13 | 7.8 | 78 | female | 2 | 19 | 7.2 | 2 | osimertinib 80 mg daily | 18.1 | false | MSS | 2026-03-15T05:35:58.134789+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_128340 | REC_0005209 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 29 | 7.7 | 67 | female | 0 | 20 | 4.6 | 5 | carboplatin + paclitaxel + pembrolizumab | 14.3 | false | MSS | 2026-03-15T05:35:58.135016+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_184292 | REC_0005210 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 23 | 7 | 67 | female | 0 | 53 | 4.6 | 5 | carboplatin + paclitaxel + pembrolizumab | 13.1 | true | MSS | 2026-03-15T05:35:58.135244+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_952659 | REC_0005211 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 19 | 14.7 | 62 | male | 0 | 13 | 5.4 | 5 | alectinib 600 mg BID | 8.7 | true | MSS | 2026-03-15T05:35:58.135479+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_535591 | REC_0005212 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 26 | 10.4 | 77 | female | 1 | 23 | 4.5 | 6 | alectinib 600 mg BID | 12.9 | false | MSI-H | 2026-03-15T05:35:58.135710+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_343781 | REC_0005213 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 27 | 10.4 | 73 | female | 2 | 15 | 3.5 | 2 | osimertinib 80 mg daily | 22.3 | false | MSI-H | 2026-03-15T05:35:58.135942+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_281155 | REC_0005214 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 27 | 15.2 | 73 | female | 1 | 18 | 3.7 | 5 | osimertinib 80 mg daily | 8.7 | true | MSI-H | 2026-03-15T05:35:58.136371+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_694195 | REC_0005215 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 24 | 10.4 | 56 | female | 0 | 8 | 6.1 | 2 | sotorasib 960 mg daily | 26.6 | true | MSS | 2026-03-15T05:35:58.136619+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_759104 | REC_0005216 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 21 | 12.4 | 81 | female | 2 | 25 | 5.7 | 4 | osimertinib 80 mg daily | 7 | false | MSS | 2026-03-15T05:35:58.136856+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_796209 | REC_0005217 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 23 | 9.1 | 53 | female | 0 | 15 | 6 | 3 | osimertinib 80 mg daily | 6.6 | true | MSS | 2026-03-15T05:35:58.137087+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_560820 | REC_0005218 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 22 | 6 | 67 | female | 0 | 9 | 6 | 4 | entrectinib 600 mg daily | 13.6 | false | MSS | 2026-03-15T05:35:58.137318+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_333334 | REC_0005219 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 28 | 14.6 | 70 | female | 2 | 2 | 4.9 | 5 | osimertinib 80 mg daily | 14 | false | MSI-H | 2026-03-15T05:35:58.137550+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_721061 | REC_0005220 | Non-small cell lung cancer | Large cell carcinoma | IVA | None (PD-L1 high) | 17 | 5.4 | 65 | female | 0 | 13 | 5.8 | 2 | pembrolizumab 200 mg q3w | 20.3 | true | MSS | 2026-03-15T05:35:58.137781+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_942829 | REC_0005221 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 23 | 4.4 | 64 | male | 1 | 10 | 4.5 | 6 | alectinib 600 mg BID | 9.8 | false | MSS | 2026-03-15T05:35:58.138016+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_881033 | REC_0005222 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 22 | 9.5 | 78 | female | 1 | 10 | 5.9 | 4 | osimertinib 80 mg daily | 13.6 | false | MSS | 2026-03-15T05:35:58.138243+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_841794 | REC_0005223 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 23 | 9.9 | 74 | female | 2 | 20 | 6.1 | 2 | entrectinib 600 mg daily | 15.3 | true | MSS | 2026-03-15T05:35:58.138472+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_439547 | REC_0005224 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None (PD-L1 high) | 21 | 6.4 | 75 | female | 2 | 40 | 5.1 | 1 | pembrolizumab 200 mg q3w | 30.1 | false | MSS | 2026-03-15T05:35:58.138704+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_208844 | REC_0005225 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 21 | 12 | 67 | female | 0 | 9 | 4.2 | 6 | entrectinib 600 mg daily | 7.2 | true | MSI-H | 2026-03-15T05:35:58.138943+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_225290 | REC_0005226 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 29 | 12.6 | 67 | female | 1 | 10 | 4.6 | 2 | sotorasib 960 mg daily | 13.3 | false | MSI-H | 2026-03-15T05:35:58.139173+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_101059 | REC_0005227 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 25 | 19.2 | 61 | male | 1 | 7 | 4.9 | 2 | osimertinib 80 mg daily | 4 | false | MSI-H | 2026-03-15T05:35:58.139457+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_416357 | REC_0005228 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 26 | 5.5 | 61 | female | 0 | 37 | 5.4 | 2 | carboplatin + paclitaxel + pembrolizumab | 21.3 | false | MSS | 2026-03-15T05:35:58.139695+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_566275 | REC_0005229 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 29 | 5.5 | 75 | female | 1 | 39 | 6.2 | 1 | carboplatin + paclitaxel + pembrolizumab | 16.4 | true | MSS | 2026-03-15T05:35:58.139929+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_798568 | REC_0005230 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 26 | 14.6 | 72 | female | 1 | 13 | 6.1 | 5 | sotorasib 960 mg daily | 13.8 | false | MSI-H | 2026-03-15T05:35:58.140192+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_397079 | REC_0005231 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 23 | 1.5 | 69 | female | 0 | 10 | 4 | 2 | osimertinib 80 mg daily | 15.4 | false | MSS | 2026-03-15T05:35:58.140427+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_951964 | REC_0005232 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 24 | 11.4 | 59 | male | 0 | 14 | 6 | 1 | osimertinib 80 mg daily | 24.1 | false | MSI-H | 2026-03-15T05:35:58.140667+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_739574 | REC_0005233 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 20 | 8.8 | 82 | female | 2 | 14 | 5.4 | 6 | osimertinib 80 mg daily | 14.5 | true | MSS | 2026-03-15T05:35:58.140900+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_103230 | REC_0005234 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 26 | 5.9 | 63 | female | 1 | 22 | 6.6 | 4 | sotorasib 960 mg daily | 8.8 | false | MSS | 2026-03-15T05:35:58.141136+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_832201 | REC_0005235 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 30 | 12.6 | 75 | female | 1 | 10 | 5.1 | 2 | osimertinib 80 mg daily | 11.2 | true | MSS | 2026-03-15T05:35:58.141371+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_764514 | REC_0005236 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 31 | 10.4 | 61 | female | 0 | 14 | 7.4 | 2 | entrectinib 600 mg daily | 20.6 | false | MSI-H | 2026-03-15T05:35:58.141606+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_850763 | REC_0005237 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 23 | 9.5 | 61 | female | 0 | 20 | 5.3 | 1 | entrectinib 600 mg daily | 22.4 | false | MSS | 2026-03-15T05:35:58.141839+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_101899 | REC_0005238 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 31 | 12.9 | 52 | male | 0 | 24 | 6.9 | 4 | osimertinib 80 mg daily | 12.2 | false | MSS | 2026-03-15T05:35:58.142073+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_102267 | REC_0005239 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 26 | 12.8 | 82 | female | 1 | 25 | 4.5 | 4 | sotorasib 960 mg daily | 10.9 | true | MSI-H | 2026-03-15T05:35:58.142305+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_949223 | REC_0005240 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 23 | 10.2 | 65 | female | 0 | 21 | 5.4 | 2 | sotorasib 960 mg daily | 13 | false | MSS | 2026-03-15T05:35:58.142599+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_925392 | REC_0005241 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 24 | 10.7 | 63 | male | 1 | 5 | 3.5 | 5 | osimertinib 80 mg daily | 15.4 | true | MSS | 2026-03-15T05:35:58.142836+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_676039 | REC_0005242 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 27 | 2.3 | 78 | female | 0 | 14 | 6.3 | 1 | carboplatin + paclitaxel + pembrolizumab | 14.2 | false | MSS | 2026-03-15T05:35:58.143065+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_966658 | REC_0005243 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 18 | 7.8 | 68 | female | 0 | 15 | 4.2 | 8 | pembrolizumab 200 mg q3w | 8.4 | false | MSS | 2026-03-15T05:35:58.143296+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_548021 | REC_0005244 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 27 | 10.4 | 67 | female | 0 | 6 | 5.5 | 5 | alectinib 600 mg BID | 4 | false | MSS | 2026-03-15T05:35:58.143532+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_935591 | REC_0005245 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 29 | 13 | 59 | male | 0 | 19 | 4 | 7 | osimertinib 80 mg daily | 7 | false | MSI-H | 2026-03-15T05:35:58.143768+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_862593 | REC_0005246 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 22 | 6.5 | 49 | female | 0 | 49 | 5.3 | 5 | carboplatin + paclitaxel + pembrolizumab | 11.2 | false | MSS | 2026-03-15T05:35:58.143994+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_848205 | REC_0005247 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 33 | 6 | 67 | female | 0 | 16 | 5.8 | 2 | osimertinib 80 mg daily | 18.1 | true | MSS | 2026-03-15T05:35:58.144291+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_930954 | REC_0005248 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 25 | 13.2 | 69 | female | 1 | 28 | 7.2 | 6 | osimertinib 80 mg daily | 9.5 | false | MSS | 2026-03-15T05:35:58.144531+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_832010 | REC_0005249 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 25 | 11.6 | 67 | female | 0 | 17 | 6.4 | 5 | osimertinib 80 mg daily | 12.7 | false | MSS | 2026-03-15T05:35:58.144769+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_973492 | REC_0005250 | Non-small cell lung cancer | Adenocarcinoma | IVA | None (PD-L1 high) | 26 | 12.5 | 68 | female | 1 | 15 | 5.8 | 2 | pembrolizumab 200 mg q3w | 28.7 | false | MSI-H | 2026-03-15T05:35:58.145003+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_236532 | REC_0005251 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 24 | 11.7 | 75 | female | 1 | 9 | 4.4 | 5 | osimertinib 80 mg daily | 11.6 | false | MSS | 2026-03-15T05:35:58.145234+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_707383 | REC_0005252 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 21 | 6.8 | 68 | female | 1 | 9 | 4.4 | 2 | alectinib 600 mg BID | 16.1 | true | MSS | 2026-03-15T05:35:58.145464+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_425387 | REC_0005253 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 19 | 14.1 | 59 | female | 0 | 19 | 6 | 6 | sotorasib 960 mg daily | 10.7 | true | MSI-H | 2026-03-15T05:35:58.145776+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_250192 | REC_0005254 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 27 | 7.4 | 68 | female | 0 | 41 | 5.8 | 1 | carboplatin + paclitaxel + pembrolizumab | 16.6 | false | MSS | 2026-03-15T05:35:58.146011+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_189304 | REC_0005255 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 36 | 6.9 | 66 | female | 0 | 26 | 5.7 | 8 | alectinib 600 mg BID | 7.7 | true | MSS | 2026-03-15T05:35:58.146246+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_167833 | REC_0005256 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 25 | 6.4 | 68 | female | 1 | 41 | 4.5 | 6 | carboplatin + paclitaxel + pembrolizumab | 9.3 | true | MSS | 2026-03-15T05:35:58.146474+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_277546 | REC_0005257 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 22 | 14.2 | 77 | female | 3 | 22 | 5.4 | 6 | entrectinib 600 mg daily | 16.4 | false | MSS | 2026-03-15T05:35:58.146708+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_147315 | REC_0005258 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 15 | 13.9 | 71 | female | 2 | 8 | 4.9 | 1 | alectinib 600 mg BID | 11 | true | MSS | 2026-03-15T05:35:58.146944+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_972313 | REC_0005259 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 29 | 6 | 64 | female | 0 | 17 | 5.3 | 6 | osimertinib 80 mg daily | 8.2 | true | MSS | 2026-03-15T05:35:58.147185+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_653226 | REC_0005260 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 26 | 5.2 | 75 | female | 1 | 40 | 4.9 | 4 | carboplatin + paclitaxel + pembrolizumab | 5.4 | true | MSS | 2026-03-15T05:35:58.147414+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_656501 | REC_0005261 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 20 | 15 | 67 | male | 0 | 7 | 6.4 | 7 | sotorasib 960 mg daily | 10.9 | false | MSS | 2026-03-15T05:35:58.147652+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_977297 | REC_0005262 | Non-small cell lung cancer | Adenocarcinoma | III | ALK fusion | 30 | 14.7 | 64 | male | 0 | 18 | 6.9 | 0 | alectinib 600 mg BID | 37 | false | MSS | 2026-03-15T05:35:58.147888+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_177458 | REC_0005263 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 26 | 12.4 | 65 | female | 1 | 20 | 4 | 5 | osimertinib 80 mg daily | 11.2 | true | MSS | 2026-03-15T05:35:58.148172+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_971762 | REC_0005264 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 24 | 12.7 | 70 | female | 2 | 18 | 6.2 | 3 | osimertinib 80 mg daily | 9.8 | false | MSI-H | 2026-03-15T05:35:58.148414+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_660335 | REC_0005265 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 26 | 11.5 | 90 | male | 1 | 21 | 5 | 1 | sotorasib 960 mg daily | 15.3 | false | MSS | 2026-03-15T05:35:58.148652+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_219986 | REC_0005266 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 19 | 13.3 | 64 | male | 1 | 18 | 7.1 | 6 | osimertinib 80 mg daily | 6.9 | false | MSI-H | 2026-03-15T05:35:58.148945+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_728092 | REC_0005267 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 28 | 6.7 | 60 | female | 1 | 11 | 7.3 | 2 | sotorasib 960 mg daily | 20.1 | true | MSS | 2026-03-15T05:35:58.149183+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_986375 | REC_0005268 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 22 | 16.5 | 85 | female | 1 | 17 | 6.5 | 4 | sotorasib 960 mg daily | 10.6 | true | MSS | 2026-03-15T05:35:58.149421+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_307875 | REC_0005269 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 21 | 11.2 | 50 | female | 0 | 14 | 3.8 | 8 | osimertinib 80 mg daily | 14.7 | false | MSI-H | 2026-03-15T05:35:58.149657+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_850950 | REC_0005270 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 26 | 11.8 | 78 | female | 1 | 5 | 4.9 | 2 | sotorasib 960 mg daily | 19.7 | true | MSI-H | 2026-03-15T05:35:58.149888+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_862629 | REC_0005271 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 28 | 12.7 | 71 | female | 2 | 13 | 5.2 | 4 | osimertinib 80 mg daily | 11.8 | true | MSS | 2026-03-15T05:35:58.150118+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_885806 | REC_0005272 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 29 | 8.5 | 82 | female | 2 | 8 | 5 | 2 | osimertinib 80 mg daily | 15.8 | false | MSS | 2026-03-15T05:35:58.150346+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_507825 | REC_0005273 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 21 | 14.2 | 61 | male | 1 | 18 | 7.2 | 2 | osimertinib 80 mg daily | 14.1 | true | MSS | 2026-03-15T05:35:58.150582+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_943369 | REC_0005274 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 26 | 11.6 | 83 | female | 1 | 17 | 5.9 | 6 | sotorasib 960 mg daily | 12.2 | false | MSI-H | 2026-03-15T05:35:58.150812+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_825979 | REC_0005275 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 21 | 9.1 | 61 | female | 1 | 21 | 6.2 | 8 | osimertinib 80 mg daily | 12.4 | true | MSS | 2026-03-15T05:35:58.151043+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_998751 | REC_0005276 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 25 | 8 | 74 | female | 1 | 15 | 5.5 | 5 | osimertinib 80 mg daily | 5.6 | true | MSS | 2026-03-15T05:35:58.151269+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_428545 | REC_0005277 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 23 | 4 | 66 | female | 1 | 70 | 5 | 2 | carboplatin + paclitaxel + pembrolizumab | 10.6 | true | MSS | 2026-03-15T05:35:58.151501+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_978169 | REC_0005278 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 26 | 20.6 | 52 | female | 0 | 28 | 4.2 | 2 | alectinib 600 mg BID | 11.8 | false | MSS | 2026-03-15T05:35:58.151737+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_324869 | REC_0005279 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 20 | 6.7 | 65 | female | 0 | 46 | 3.7 | 7 | carboplatin + paclitaxel + pembrolizumab | 12.4 | false | MSS | 2026-03-15T05:35:58.152013+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_436707 | REC_0005280 | Non-small cell lung cancer | Squamous cell carcinoma | III | None (PD-L1 high) | 20 | 6.8 | 65 | female | 1 | 73 | 5.9 | 0 | pembrolizumab 200 mg q3w | 27.3 | false | MSS | 2026-03-15T05:35:58.152280+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_497854 | REC_0005281 | Non-small cell lung cancer | Adenocarcinoma | III | EGFR L858R | 26 | 7.2 | 62 | female | 1 | 12 | 5.5 | 0 | osimertinib 80 mg daily | 45.2 | true | MSS | 2026-03-15T05:35:58.152518+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_708262 | REC_0005282 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 20 | 16.1 | 64 | female | 0 | 21 | 3.9 | 2 | sotorasib 960 mg daily | 25.2 | false | MSS | 2026-03-15T05:35:58.152754+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_118797 | REC_0005283 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 22 | 6.5 | 75 | female | 2 | 6 | 5.2 | 6 | carboplatin + paclitaxel + pembrolizumab | 11.8 | false | MSS | 2026-03-15T05:35:58.152983+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_163889 | REC_0005284 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 20 | 11.3 | 71 | female | 1 | 24 | 5.9 | 5 | entrectinib 600 mg daily | 18.1 | true | MSI-H | 2026-03-15T05:35:58.153216+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_548163 | REC_0005285 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 27 | 14.2 | 80 | female | 2 | 15 | 5 | 5 | entrectinib 600 mg daily | 8.7 | true | MSI-H | 2026-03-15T05:35:58.153449+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_836324 | REC_0005286 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 25 | 5.6 | 53 | male | 0 | 39 | 6.2 | 2 | carboplatin + paclitaxel + pembrolizumab | 21.6 | true | MSS | 2026-03-15T05:35:58.153676+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_436719 | REC_0005287 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 32 | 4.2 | 69 | female | 0 | 70 | 7.5 | 9 | carboplatin + paclitaxel + pembrolizumab | 11.6 | false | MSS | 2026-03-15T05:35:58.153906+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_977555 | REC_0005288 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 23 | 7.7 | 68 | female | 1 | 9 | 7.5 | 8 | entrectinib 600 mg daily | 13.5 | false | MSS | 2026-03-15T05:35:58.154137+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_526006 | REC_0005289 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 16 | 15.2 | 78 | female | 2 | 18 | 6.9 | 5 | alectinib 600 mg BID | 7.8 | false | MSS | 2026-03-15T05:35:58.154369+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_763222 | REC_0005290 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 30 | 15.2 | 65 | female | 0 | 26 | 5.2 | 1 | sotorasib 960 mg daily | 18.7 | true | MSS | 2026-03-15T05:35:58.154607+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_308657 | REC_0005291 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 22 | 12.5 | 71 | female | 2 | 17 | 8.4 | 1 | osimertinib 80 mg daily | 22.6 | false | MSI-H | 2026-03-15T05:35:58.154837+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_681014 | REC_0005292 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 21 | 14.7 | 74 | male | 2 | 13 | 5.9 | 2 | entrectinib 600 mg daily | 14.2 | true | MSS | 2026-03-15T05:35:58.155115+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_643353 | REC_0005293 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 26 | 11.8 | 66 | male | 0 | 8 | 3.9 | 4 | osimertinib 80 mg daily | 13 | false | MSI-H | 2026-03-15T05:35:58.155359+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_601575 | REC_0005294 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 21 | 8.6 | 81 | female | 1 | 16 | 4.2 | 1 | osimertinib 80 mg daily | 18.3 | false | MSS | 2026-03-15T05:35:58.155585+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_774303 | REC_0005295 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 25 | 11.2 | 58 | female | 1 | 19 | 4.8 | 1 | alectinib 600 mg BID | 18.1 | false | MSI-H | 2026-03-15T05:35:58.155825+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_254239 | REC_0005296 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 26 | 8.6 | 64 | female | 0 | 20 | 5.7 | 7 | pembrolizumab 200 mg q3w | 12.5 | true | MSS | 2026-03-15T05:35:58.156055+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_621692 | REC_0005297 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 25 | 9 | 78 | female | 1 | 12 | 6.1 | 4 | sotorasib 960 mg daily | 17.3 | true | MSS | 2026-03-15T05:35:58.156386+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_575096 | REC_0005298 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 27 | 10.9 | 86 | female | 2 | 43 | 6.7 | 2 | carboplatin + paclitaxel + pembrolizumab | 15.2 | true | MSS | 2026-03-15T05:35:58.156634+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_752608 | REC_0005299 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 16 | 6.4 | 67 | female | 0 | 9 | 6.5 | 9 | osimertinib 80 mg daily | 12.6 | true | MSS | 2026-03-15T05:35:58.156866+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_293381 | REC_0005300 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 24 | 12.5 | 90 | female | 2 | 19 | 3.1 | 2 | entrectinib 600 mg daily | 10.3 | false | MSS | 2026-03-15T05:35:58.157097+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.